Retatrutide just posted 28.7% average weight loss in Phase 3. Ozempic does 14.9%. Mounjaro does 22%. The numbers are real — but they don't tell the whole story. Here's the actual comparison that matters if you're deciding what to use or considering switching.
Retatrutide wins on weight loss. It's not close. But it isn't FDA approved yet, it costs more, the adaptation period is longer, and if you're on Mounjaro and doing well — switching to something unregulated may not make sense for you. Here's the full breakdown.
Retatrutide's 28.7% result from the TRIUMPH-4 Phase 3 trial published in December 2025 is the highest ever recorded for a weight loss medication — approaching the 30% typically seen with bariatric surgery. At 12mg, the top dose in trials, some participants lost over 60 pounds.
The reason retatrutide outperforms both is its triple-receptor mechanism. Ozempic targets one receptor (GLP-1). Mounjaro targets two (GLP-1 and GIP). Retatrutide hits all three: GLP-1, GIP, and glucagon. The glucagon component is the differentiator — it increases energy expenditure and drives hepatic fat oxidation in a way the other two can't replicate.
| Factor | Ozempic / Wegovy | Mounjaro / Zepbound | Retatrutide |
|---|---|---|---|
| Mechanism | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Avg weight loss | 14.9% | ~22% | 28.7% (Phase 3) |
| FDA approved | Yes | Yes | Not yet (2026/2027) |
| Food noise reduction | Significant | Stronger | Strongest reported |
| Muscle loss ratio | ~35-40% of total wt | ~35-40% of total wt | ~38% of total wt (similar) |
| Heart rate increase | Minimal | Minimal | Transient increase noted |
| No plateau | Plateau common | Slower plateau | Continued loss through week 68 |
| Dosing | Once weekly | Once weekly | Once weekly |
| GI side effects | Common during escalation | Similar to sema | Similar, peaks wks 4-10 |
| Cost (compounded) | ~$150-300/mo | ~$200-400/mo | Higher, varies widely |
The most common reason people look at retatrutide in 2026 is that they've stalled on semaglutide or tirzepatide. Scientists published new research in May 2026 explaining exactly why Ozempic and Wegovy weight loss eventually plateaus — the brain's cAMP-dependent mechanisms in GLP-1R-expressing neurons adapt over time, reducing the medication's appetite-suppressing effect.
Retatrutide's glucagon component appears to delay this plateau mechanism. In TRIUMPH-4, participants continued losing weight through the entire 68-week period without hitting the stall that semaglutide users typically experience around weeks 36-52. For people who've plateaued on Mounjaro, retatrutide is increasingly discussed as the next step — though formal switching protocols won't exist until after FDA approval.
The most common concern about retatrutide is muscle loss. Huberman flagged it. Reddit amplified it. The actual data: retatrutide's lean mass loss ratio is approximately 38% of total weight lost — similar to the 35-40% range seen with semaglutide and tirzepatide. Despite losing more total weight, you don't lose a disproportionately higher percentage as muscle. Resistance training and high protein intake matter regardless of which medication you're on.
Food noise — the constant mental chatter about food, cravings, and eating — is one of the most searched topics in the GLP-1 community because it's the effect that most profoundly changes people's lives. Most users say eliminating food noise is more impactful than the weight loss itself.
Semaglutide reduces food noise significantly for most users. Tirzepatide reduces it further. Retatrutide users in trials and community reports consistently describe the most complete elimination of food noise of any medication — the combination of GLP-1 appetite suppression, GIP-enhanced satiety, and glucagon-driven metabolic acceleration creates an effect that goes beyond what single or dual-receptor agents produce.
For people who tried Ozempic and found food noise still present, or who plateaued on Mounjaro with cravings returning — this is the primary driver of interest in retatrutide.
FDA approval. As of mid-2026 retatrutide is still in Phase 3 trials. It cannot be prescribed legally in the US. People accessing it are sourcing compounded or research-grade versions — which vary widely in purity and quality. Eli Lilly's official commercial version doesn't exist yet.
Heart rate. Retatrutide causes a transient increase in resting heart rate during escalation that's more pronounced than semaglutide or tirzepatide. For most people this is temporary and resolves, but it requires monitoring — especially for anyone with existing cardiovascular conditions.
Established safety record. Ozempic and Wegovy have years of real-world safety data. Retatrutide has clinical trial data. That's a meaningful difference. Long-term effects at scale are still unknown.
Simplicity. The escalation schedule is longer and the adaptation period more variable than semaglutide. For someone who wants the most straightforward protocol, semaglutide or tirzepatide is still the answer.
Retatrutide is not FDA approved as of mid-2026. Anyone accessing it is using compounded or research-grade versions. Quality, purity, and dosing accuracy vary. If you're considering retatrutide, work with a licensed provider who can source from a reputable 503A compounding pharmacy and monitor your response.
You're getting good results and tolerating it well. You want the most established safety record. You have cardiovascular disease (Wegovy has FDA approval for CV risk reduction). You need the most affordable option. You're not plateaued and still losing.
You've plateaued on semaglutide. You want significantly stronger appetite suppression. You want more weight loss with the same FDA-approved safety standards. You have type 2 diabetes and want Mounjaro's dual-indication approval.
You've plateaued on tirzepatide and need the next level. You're working with a provider who can monitor your response properly. You understand the regulatory status and are sourcing carefully. You want the maximum possible weight loss and can manage a more complex adaptation period.
Peptide Companion is built for all GLP-1 and peptide users — semaglutide, tirzepatide, retatrutide, BPC-157, and more. Companion Intelligence monitors your protocol response daily and tells you what's actually changing.
Get the App →Based on 2026 Phase 3 TRIUMPH-4 trial data, retatrutide at 12mg achieved 28.7% average body weight loss at 68 weeks compared to Ozempic's 14.9%. Retatrutide's triple-receptor mechanism produces significantly greater weight loss. However, retatrutide is not yet FDA approved as of mid-2026.
Retatrutide outperforms tirzepatide (Mounjaro/Zepbound) in weight loss — 28.7% vs approximately 22% in trials. The key difference is retatrutide's additional glucagon receptor activation. However, tirzepatide is FDA approved and commercially available in 2026 while retatrutide is still in trials.
As of mid-2026, retatrutide has multiple active Phase 3 trials with results expected through 2026 and 2027. FDA approval is expected in late 2026 or 2027 based on current trial timelines. Eli Lilly's TRIUMPH-4 Phase 3 data published in December 2025 showed 28.7% weight loss at 68 weeks.
Current data suggests retatrutide causes a similar proportion of lean mass loss (approximately 38% of total weight lost) to other GLP-1 medications. Despite faster overall weight loss, retatrutide does not appear to cause disproportionately more muscle loss relative to fat loss.
Formal switching protocols won't exist until retatrutide receives FDA approval. Currently, people transitioning do so through compounding pharmacies under provider supervision. The general approach used in practice involves completing your current semaglutide cycle, then beginning retatrutide at the lowest dose with standard escalation.
Both share GI side effects — nausea, vomiting, diarrhea — especially during dose escalation. Retatrutide additionally causes a transient heart rate increase that's more pronounced than with semaglutide. In TRIUMPH-4, nausea affected approximately 43% of participants on 12mg, with most cases mild to moderate and clustered during escalation.